The Value of Technology to Reduce Barriers to Clinical Trial Diversity and Facilitate the Development of Patient-Centric Medicine


Cross N1, Dawson M2
1Lightning Health, London, LON, UK, 2Lightning Health, Tunbridge Wells, UK


Historically, participants of clinical trials have not been representative of the target patient pool, with women, ethnic minorities, and the elderly being consistently under-represented. This lack of diversity in clinical research can have significant impacts on understanding the effectiveness and safety of a treatment, with more frequent adverse effects occurring in under-represented groups. Barriers to patient participation include medical mistrust, eligibility requirements, and lack of access. This research aims to explore how advances in technology can increase patient centricity in trials, reduce burden of trial participation, and increase access to a broader and more diverse pool of patients.


A primary research programme was conducted with payer and HTA stakeholders, alongside KOLs in the US, UK and Germany, to explore their perceptions of the barriers to clinical trial diversity, with a focus on oncology, and how technology can increase representation within trials. Stakeholders provided insights on the key implications of a lack of trial diversity on patients and society, and how increasing digitilisation of clinical landscapes can address these issues.


KOLs rated medical mistrust and lack of access to trials as key barriers to recruiting a diverse trial population and acknowledged that the inclusion of certain sub-groups of patients can increase risks. Payers would value measures to increase the representation of real-world patient types within clinical development programmes. Across markets, the increased use of digital technologies was considered a valuable strategy to address these issues, alongside flexibility in trial design.


Stakeholders across key global markets acknowledge the that a lack of diversity in clinical research can have major scientific, medical, and moral implications. By developing strategies that utilise advances in technology to reduce barriers to patient enrollment, the diversity of clinical trials can be increased, improving access to new medicines across all socio-demographics.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)




Patient-Centered Research, Study Approaches

Topic Subcategory

Adherence, Persistence, & Compliance, Clinical Trials, Patient Behavior and Incentives, Patient Engagement


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now